Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Goserelin may offer ovarian protection when used concurrently with chemotherapy
February 23rd, 2006
Goserelin may offer ovarian protection when used concurrently with chemotherapy. According to a report from Germany, "Gonadotropin-releasing hormone analogs are, alongside tamoxifen, one of the most commonly used drugs in the treatment of pre-/perimenopausal endocrine-responsive breast cancer. Goserelin, as a principal agent of this class of drugs, is mainly investigated in clinical trials." A. Rody and colleagues of the J.W. Goethe University in Frankfurt stated, "The indirect comparison of goserelin with tamoxifen as a single drug in the adjuvant setting showed similar efficacy. Furthermore, goserelin is as effective as cyclophosphamide,...
Source: Women's Health Weekly (2006-02-23)
|
